
Keywords: ABC; ATP-binding cassette; CFDA; carboxy-2',7'-dichlorofluorescein diacetate; MDR; multidrug resistance; NC2; negative cofactor 2; NSCLC; non-small cell lung cancer; Pt; platinum; SRB; sulforhodamine B; Belinostat; Platinum anticancer drug; Drug resis